Sarepta Therapeutics (SRPT) Upgraded to “Buy” by BidaskClub

BidaskClub upgraded shares of Sarepta Therapeutics (NASDAQ:SRPT) from a hold rating to a buy rating in a report issued on Saturday.

Other analysts have also recently issued reports about the company. Oppenheimer restated a buy rating and issued a $76.00 target price on shares of Sarepta Therapeutics in a report on Monday, October 16th. Goldman Sachs Group restated a buy rating and issued a $71.00 target price on shares of Sarepta Therapeutics in a report on Friday, October 6th. Royal Bank of Canada restated a buy rating and issued a $64.00 target price on shares of Sarepta Therapeutics in a report on Tuesday, October 3rd. Instinet restated a buy rating and issued a $84.00 target price on shares of Sarepta Therapeutics in a report on Monday, October 2nd. Finally, Robert W. Baird restated a buy rating and issued a $101.00 target price on shares of Sarepta Therapeutics in a report on Tuesday, October 17th. Two equities research analysts have rated the stock with a sell rating, four have issued a hold rating and eighteen have issued a buy rating to the stock. The stock currently has an average rating of Buy and an average price target of $63.88.

Shares of Sarepta Therapeutics (NASDAQ SRPT) traded up $2.53 on Friday, hitting $61.52. The company had a trading volume of 2,217,156 shares, compared to its average volume of 2,388,300. The company has a debt-to-equity ratio of 0.04, a current ratio of 10.44 and a quick ratio of 9.52. Sarepta Therapeutics has a 52-week low of $26.26 and a 52-week high of $61.89. The stock has a market capitalization of $3,980.00, a PE ratio of -30.16 and a beta of 1.37.

Sarepta Therapeutics (NASDAQ:SRPT) last issued its quarterly earnings results on Wednesday, October 25th. The biotechnology company reported ($0.20) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.86) by $0.66. Sarepta Therapeutics had a negative return on equity of 51.72% and a negative net margin of 112.08%. The firm had revenue of $45.95 million during the quarter, compared to analysts’ expectations of $41.29 million. During the same period in the previous year, the business earned ($0.95) earnings per share. sell-side analysts predict that Sarepta Therapeutics will post -3.07 EPS for the current year.

In related news, Director Hans Lennart Rudolf Wigzell sold 6,667 shares of the stock in a transaction dated Thursday, November 30th. The stock was sold at an average price of $55.89, for a total transaction of $372,618.63. Following the transaction, the director now owns 13,333 shares of the company’s stock, valued at approximately $745,181.37. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, SVP Shamim Ruff sold 10,000 shares of the stock in a transaction dated Monday, November 6th. The stock was sold at an average price of $55.00, for a total value of $550,000.00. Following the transaction, the senior vice president now directly owns 37,045 shares in the company, valued at approximately $2,037,475. The disclosure for this sale can be found here. 9.60% of the stock is currently owned by corporate insiders.

Institutional investors and hedge funds have recently bought and sold shares of the stock. Jennison Associates LLC increased its holdings in Sarepta Therapeutics by 103.9% during the 3rd quarter. Jennison Associates LLC now owns 1,143,853 shares of the biotechnology company’s stock worth $51,885,000 after purchasing an additional 582,894 shares during the period. Alyeska Investment Group L.P. purchased a new stake in Sarepta Therapeutics during the 3rd quarter worth about $26,011,000. Voya Investment Management LLC increased its holdings in Sarepta Therapeutics by 2,786.1% during the 2nd quarter. Voya Investment Management LLC now owns 568,525 shares of the biotechnology company’s stock worth $19,165,000 after purchasing an additional 548,826 shares during the period. Gilder Gagnon Howe & Co. LLC increased its holdings in Sarepta Therapeutics by 3,599.4% during the 3rd quarter. Gilder Gagnon Howe & Co. LLC now owns 534,087 shares of the biotechnology company’s stock worth $24,226,000 after purchasing an additional 519,650 shares during the period. Finally, HealthCor Management L.P. increased its holdings in Sarepta Therapeutics by 31.1% during the 2nd quarter. HealthCor Management L.P. now owns 2,031,890 shares of the biotechnology company’s stock worth $68,495,000 after purchasing an additional 481,890 shares during the period. 82.02% of the stock is currently owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION WARNING: “Sarepta Therapeutics (SRPT) Upgraded to “Buy” by BidaskClub” was published by TrueBlueTribune and is the sole property of of TrueBlueTribune. If you are viewing this report on another domain, it was copied illegally and reposted in violation of US & international copyright & trademark legislation. The legal version of this report can be accessed at https://www.truebluetribune.com/2018/01/15/sarepta-therapeutics-srpt-upgraded-to-buy-by-bidaskclub-2.html.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD).

Analyst Recommendations for Sarepta Therapeutics (NASDAQ:SRPT)

Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply